Canada’s Tilray (NASDAQ:TLRY) has now surpassed Canopy Growth Corporation(NYSE:CGC) as the largest marijuana company in the world by market capitalization. The bizarre part is that Tilray’s production capacity pales in comparison to Canopy’s at present. As a result, Wall Street has Canopy’s 2019 sales coming in at over $130 million higher than Tilray’s under current projections. Tilray’s stock, therefore, could be seriously overvalued, implying that cannabis investors might want to look for greener pastures moving forward.
With this theme in mind, I think marijuana investors might want to check out both MariMed(NASDAQOTH:MRMD) and The Green Organic Dutchman Holdings Ltd.(NASDAQOTH:TGODF) right now. While neither is an out-and-out bargain in the classic sense, they are both better values than Tilray at current share prices. Read on to find out more…
A cannabis expert
The small-cap American company MariMed might not look like a vastly better buy than Tilray right now, but I think it will turn out to be a far superior long-term investment for a couple of reasons.
First, MariMed has the strategic advantage of being physically located in the most valuable pot market in the world: the United States. Legal pot sales in the U.S., after all, are expected to come in at over 10 times those of both Canada and Latin America, once federal prohibition ends.
MariMed is thus sitting on a gold mine. Although the coveted U.S. market might remain off-limits under the current administration, industry insiders widely believe that it’s only a matter of time until prohibition at the federal level is finally shelved. A whopping 31 states have already voted to permit cannabis use for medical purposes, and 9 states allow the drug to be consumed recreationally. Put simply, the U.S. is edging closer and closer to full-scale decriminalization of the drug…
Continue reading at THE MOTLEY FOOL